Researcher Spotlight: Christina Poh, MD City of Hope Nodal T follicular helper (TFH) cell lymphoma is an aggressive type of blood cancer that often responds poorly to frontline therapies such as chemotherapy and bone marrow transplant. Dr. Poh’s research aims…
Researcher Spotlight: Andrew Jallouk, MD, PhD Vanderbilt University Medical Center Chimeric antigen receptor (CAR) T-cell therapy is a lifesaving treatment option for many patients with relapsed or refractory lymphoma. Current CAR T-cell therapies are engineered from a patient’s own cells,…
Researcher Spotlight: Mengyang Di, MD, PhD University of Washington Bispecific T-cell engagers have emerged as an important treatment option for the management of relapsed or refractory follicular lymphoma. These therapies harness the anti-cancer activity of the patient’s own T cell…
Researcher Spotlight: Alexander Boardman, MD Memorial Sloan Kettering Cancer Center Dr. Boardman is an attending medical oncologist specializing in the study and treatment of lymphoma. His work focuses on the development of novel therapies for patients with diffuse large B-cell…
Researcher Spotlight: Neha Akkad, MD The University of Texas MD Anderson Cancer Center Patient-reported outcomes (PROs) are tools used to directly measure the experiences of patients rather than as interpreted by clinicians or researchers. Incorporation of PROs into clinical trials…
Researcher Spotlight: Eduardo Edelman Saul, MD University of Texas MD Anderson Cancer Center Limited treatment options are available after frontline chemotherapy for peripheral T-cell lymphoma (PTCL), leading to poor clinical outcomes for patients who relapse. Golidocitinib, a selective Janus kinase…
Researcher Spotlight: Mallorie Heneghan, MD The University of Utah Paul Walker Schaffel Scholar Adolescents and young adults (AYAs) with lymphoma often have poor outcomes, with variable presentations observed between age groups. In particular, Dr. Heneghan is interested in understanding how…
Researcher Spotlight: Jennifer Huang, MD, PhD Fred Hutchinson Cancer Center Kanti R. Rai, MD Clinical Scholar Lisocabtagene maraleucel (liso-cel) is a chimeric antigen receptor (CAR) T-cell therapy that can be used to treat patients with relapsed or refractory chronic lymphocytic…
Researcher Spotlight: Alex Niu, MD Roswell Park Cancer Institute Eric Cohen Distinguished Scholar Chimeric antigen receptor (CAR) T-cell therapies represent a promising treatment option for many patients with relapsed lymphoma, but some patients still do not respond to therapy. By…
Researcher Spotlight: Evelyn Orlando, MD Weill Cornell Medicine Kaine Family Scholar Immunosuppressant medications used to prevent rejection after organ transplant can increase the likelihood of infection with Epstein-Barr virus (EBV). EBV infection in immunosuppressed individuals can lead to a variety…
